Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



(1)

wherein:

Cy is a group of Formula (2):



(2)

~~C_{3-7} cycloalkyl or phenyl;~~

R_1, R_2, R_3, R_4 and R_5 are hydrogen, halogen, or hydroxy~~, amino, trifluoromethyl or nitrile~~ and at least one of R_1, R_2, R_3, R_4 and R_5 is halogen~~, trifluoromethyl or nitrile~~;

R_6 is hydrogen~~, optionally substituted straight-chained or branched C_{1-3} alkyl, amino or hydroxy~~;

R_7 is ~~hydrogen, optionally substituted~~ straight-chained or branched C_{1-3}alkyl, substituted with one or more hydroxyl groups, or amino optionally substituted with one or

more ~~of the same or different kinds of~~ straight-chained or branched C_{1-3} alkyl groups which many be the same or different~~, or hydroxy~~;

R_8 is hydrogen, methyl or ethyl;

R_9 is ~~optionally substituted~~ straight-chained or branched C_{1-6} alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of phenyl, para-hydroxyphenyl, para-fluorophenyl, para-chlorophenyl, C3-7 cycloalkyl, halogen and thienyl, ~~optionally substituted straight chained or branched C_{2-6}alkenyl, optionally substituted straight chained or branched C_{2-6}alkynyl, C_{3-7}cycloalkyl~~; or ~~optionally substituted~~ phenyl;

R_{20} is hydrogen ~~or straight chained or branched C_{1-3}alkyl or R_9 and R_{20} may together form C_{3-7}cycloalkyl~~;

R_{10} is hydrogen or methyl or ethyl ~~straight chained or branched C_{1-3}alkyl~~;

R_{11} is ~~hydrogen,~~ straight-chained or branched C_{1-3} alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino ~~optionally substituted with one or more of the same or different straight chained or branched C_{1-3} alkyl, 3 to 7 membered cyclic amino optionally substituted with hydroxyl, amino, carboxyl, carbamoyl or methyl~~; hydroxyl,

~~methoxy, halogen,~~ carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino and methanesulfonylamino, and -CO-$N(R_{14})R_{15}$~~, carboxyl~~;

R_{12} is hydroxy~~ or OR_{16}~~;

R_{13}~~ is hydrogen,~~ straight-chained or branched C_{1-6} alkyl, ~~straight-chained or branched C_{2-6}alkenyl, straight-chained or branched C_{2-6}alkynyl or a group of Formula (3):~~



;

R_{14} and R_{15}, which may be the same or different, are each hydrogen, straight-chained or branched C_{1-3} alkyl optionally substituted with ~~straight-chained or branched C_{1-3} alkoxy optionally substituted with hydroxyl, amino, carboxyl or carbamoyl;~~ hydroxyl~~; amino; methylamino; dimethylamino; carbamoyl~~ or methanesulfonyl~~; optionally substituted straight-chained or branched C_{1-4} alkyl~~, C_{3-7}cycloalkyl, straight-chained or branched C_{1-4} alkoxy, straight-chained or branched C_{1-4} alkylsulfonyl, or pyridyl; a heterocyclic ring;~~

~~R_{16} is straight-chained C_{1-4} alkyl;~~

~~R_{17} is hydrogen or methyl;~~

R_{18} and R_{19} together form cycloalkyl or C_{3-7} cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl ~~or methylene~~;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2);

or a pharmaceutically acceptable salt thereof.

3. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

4. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen or R_2 and R_3 are the same kind of halogen;

or a pharmaceutically acceptable salt thereof.

5. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen and R_1, R_2, R_4 and R_5 are hydrogen, or R_2 and R_3 are the same kind of halogen and R_1, R_4 and R_5 are hydrogen; or a pharmaceutically acceptable salt thereof.

Claims 6-13. (Canceled)

14. (Previously presented) The compound according to claim 1, wherein R_7 in Formula (1) is hydrogen or amino optionally substituted with one or more of the same of different kinds of straight-chained or branched C_{1-3} alkyl; or a pharmaceutically acceptable salt thereof.

15. (Previously presented) The compound according to claim 1, wherein R_8 in Formula (1) is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.

16. (Previously presented) The compound according to claim 1, wherein R_9 in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl;
or a pharmaceutically acceptable salt thereof.

Claims 17-18. (Cancelled)

19. (Currently Amended) The compound according to claim 1, wherein R_{11} in Formula (1) is methyl, hydroxymethyl,

carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, ~~carbamoyl,~~ ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, ~~cyclopropylcarbamoyl,~~ tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,;

or a pharmaceutically acceptable salt thereof.

Claim 20 Cancelled

21. (Currently Amended) The compound according to claim 1, wherein R_{13} in Formula (1) is isopropyl, tert-butyl (tBu), or 1,1-dimethylpropyl ~~or 1,1-dimethyl-2-propenyl~~;

or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

22. (Currently Amended) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;

~~R_6 is hydrogen or methyl;~~

~~R_7 is hydrogen or optionally substituted amino optionally substituted with one or more of the same or different straight-chained or branched C_{1-3} alkyl;~~

R_8 is hydrogen or methyl;

R_9 is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl~~,~~ phenyl~~, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;~~

~~R_{20} is hydrogen;~~

~~R_{10} is hydrogen or methyl~~;

R_{11} is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, ~~carbamoyl,~~ methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, ~~, tert-cyclopropylcarbamoyl, butylcarbamoyl,~~ , methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl~~,~~;

~~R_{12} is hydroxy;~~

R_{13} is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl~~,~~ or 1,1-dimethyl-2-propenyl;

or a pharmaceutically acceptable salt thereof.

23. (Previously presented) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3,4-F_2)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-

pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-

methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val- N-Et-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2SO_2CH_3$, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Me-

Tyr(3-tBu)- NHEt, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHiPr;

or a pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Currently Amended) A compound of Formula (4):



(4)

wherein

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7' is ~~hydrogen,~~ straight-chained or branched C_{1-3}alkyl substituted with one or more ~~optionally having at least one~~ protected hydroxyl groups ~~substituent~~, or protected amino optionally substituted with ~~having at least~~ one or more ~~substituent of the same or different~~ straight-chained or branched C_{1-3} alkyl groups which may be the same or different ~~or protected hydroxyl~~; and

R_{11}" is ~~hydrogen,~~ straight-chained or branched C_{1-3} alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino ~~optionally substituted with one or more of the same of different straight-chained or branched C_{1-3} alkyl, 3 to 7 membered cyclic amino optionally substituted with hydroxyl, amino, carboxyl, carbamoyl or methyl, hydroxyl, methoxy, halogen~~; carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino, and methanesulfonylamino, and -CO-

$N(R_{14})R_{15}$, wherein R_{14} and R_{15} are as defined in claim 1, ~~carboxyl, straight-chained or branched C_{1-3}alkyl having a protected amino~~;

or a pharmaceutically acceptable salt thereof.

29. (Currently Amended) A compound of Formula (5):



(5)

wherein:

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7" is ~~hydrogen,~~ straight-chained or branched C_{1-3}alkyl ~~optionally having at least optionally~~ substituted with one or more optionally protected hydroxyl groups ~~substituent~~ or amino optionally ~~having at least~~ substituted with one or more ~~substituents which are the same or~~ different straight-chained or branched C_{1-3} alkyl groups which may be the same or different~~, or optionally protected hydroxy~~; and

R_{11}' is ~~hydrogen,~~ straight-chained or branched C_{1-3}alkyl optionally substituted with one or more groups ~~having at least one protected substituent s~~ which may be the same or different and are selected from the group consisting of protected amino ~~optionally substituted with one or more~~

~~straight- chained or branched C_{1-3} alkyl; protected 3- to 7-membered cyclic amino optionally substituted with protected hydroxyl, protected amino, protected carboxyl or protected carbamoyl~~; protected hydroxyl~~,~~ protected carbamoyl~~,~~ protected ureide~~,~~ protected guanidyl~~,~~ protected N'-cyano-N"-methylguanidyl~~,~~ protected sulfamoylamino~~,~~ protected carbamoylmethylamino and protected methanesulfonylamino;~~, and~~ $-CO-N(R_{14})R_{15}$ wherein R_{14} and R_{15} are ~~as~~ those defined in claim 1 which are appropriately protected~~, carboxyl~~ or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



(6)

wherein:

R_8 is hydrogen, methyl or ethyl ~~optionally substituted straight-chained or branched C_{1-3} alkyl, optionally substituted amino, or hydroxy~~;

R_9, is ~~optionally substituted~~ straight-chained or branched C_{1-6} alkyl optionally substituted with one or more groups which may be the same or different ant are selected from the group consisting of phenyl, para-hydroxyphenyl, para-fluorophenyl, para-chlorophenyl, C_{3-7} cycloalkyl, halogen and

thienyl~~, optionally substituted straight-chained or branched C_{2-6} alkenyl, optionally substituted straight-chained or branched C_{2-6} alkynyl, C_{3-7} cycloalkyl or optionally substituted phenyl~~;

R_{20} is hydrogen or methyl or~~straight-chained or branched C_{1-3} alkyl; or R_9 and R_{20} may together form C_{3-7} cycloalkyl~~;

R_{10} is hydrogen or methyl or ethyl~~straight-chain or branched C_{1-3} alkyl~~;

R_{12} is hydroxy~~ or OR_{16}~~;

R_{13} is ~~hydrogen,~~ straight-chained or branched C_{1-6} alkyl~~, straight-chained or branched C_{2-6} alkenyl, straight-chained or branched C_{2-6} alkynyl or a group of Formula (3)~~



~~Wherein R_{17} is hydrogen or methyl,~~

~~R_{18} and R_{19} together form cycloalkenyl or C_{3-7} cycloalkenyl~~; and

Y is carbonyl~~ or methylene~~;

P_1 is hydrogen or a protecting group of amine; and

R_{11}''' is ~~hydrogen,~~ straight-chained or branched C_{1-3}alkyl, carboxyl, straight-chained or branched C_{1-3}alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino

~~optionally substituted with one or more of the same or different straight-chained or branched C_{1-3} alkyl; 3- to 7-membered cyclic amino optionally substituted with hydroxyl, amino, carboxyl, carbamoyl or methyl;~~ hydroxyl~~;~~, methoxy~~;~~, halogen~~;~~, carbamoyl~~;~~, methanesulfonyl~~;~~, ureide~~;~~, guanidyl~~;~~, N'-cyano-N"-methylguanidyl~~;~~, sulfamoylamino~~;~~, carbamoylmethylamino and methanesulfonylamino; ~~carboxyl,~~ straight-chained or branched C_{1-3} alkyl having protected amino or ~~an optionally substituted heterocyclic ring, or~~ and -CO-$N(R_{14})R_{15}$ wherein R_{14} and R_{15}, which may be the same or different, are hydrogen, ~~optionally substituted~~ straight-chained or branched C_{1-4} alkyl optionally substituted with hydroxy, C_{3-7} cycloalkyl, straight-chained or branched C_{1-4} alkoxy, straight-chained or branched C_{1-4}alkylsulfonyl, or pyridyl ~~a heterocyclic ring, carboxyl, straight-chained or branched C_{1-3}alkyl having protected amino or an optionally substituted heterocyclic ring~~;

or a pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)

35. (Previously Presented) The compound according to claim 1, wherein the substitution of the optionally substituted straight-chained or branched C_{1-3} alkyl as R_7 in formula (1) is halogen, hydroxyl or amino.